Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

SPECIAL REPORT

Skin Cancer

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2

Amyloidosis

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up

Br J Haematol

Basset M, Kimmich CR, Schreck N, Krzykalla J, Dittrich T, Veelken K, Goldschmidt H, Seckinger A, Hose D, Jauch A, Müller-Tidow C, Benner A, Hegenbart U, Schönland SO

doi: 10.1111/bjh.17685

Gastrointestinal CancerGenitourinary Cancer

Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis

Clin Genitourin Cancer.

Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ

doi: 10.1016/j.clgc.2016.12.005.

Genitourinary Cancer

Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results

healthbook TIMES Oncology Hematology

Alexander Meisel

doi: DOI: 10.36000/hbT.OH.2021.08.041

Genitourinary Cancer

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

BJU Int

Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Baenziger O, Gibbs P, Tran B

doi: 10.1111/bju.15364

Genitourinary Cancer

First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Eur Urol.

Wallis CJD, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, Goldberg H, Boorjian SA, Leibovich B, Kulkarni GS, Shah PS, Bjarnason GA, Heng DYC, Satkunasivam R, Finelli A

doi: 10.1016/j.eururo.2018.03.036.

RECOMMENDED

Further Publications

Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review

★ 2 Recommended by Prof. Dr Christoph Renner, Faculty Member

JAMA.

Gertz MA, Dispenzieri A

doi: 10.1001/jama.2020.5493.

EHA^® 25 Virtual

Multiple Myeloma (MM)

Related content

Recent Developments in Metastatic Breast Cancer

Bavencio® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma1,2

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up

Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis

Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review

Amyloid light-chain (AL) amyloidosis

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2